The Food and Drug Administration yesterday issued guidance for the development of a SARS-CoV-2 vaccine, outlining key considerations to satisfy requirements for chemistry, manufacturing and control, nonclinical and clinical data.

The agency said the current goal of vaccine development programs should be “to support traditional FDA approval by conducting studies to directly evaluate the ability of the vaccine to protect humans from SARS-CoV-2 infection and/or disease.”

FDA also authorized the emergency use of the molecular-based LifeHope 2019-nCoV Real-Time RT-PCR Diagnostic Panel. The agency concluded that the qualitative test’s known and potential benefits outweigh the risks during the COVID-19 public health emergency.

Related News Articles

Headline
A series of free videos from Med Tac offers guidance on how essential workers and the public can stay safe during the COVID-19 public health emergency.…
Headline
The AHA, American Medical Association, American Society of Health-System Pharmacists, and United States Pharmacopeia last week convened a virtual summit to…
Headline
The National Institutes of Health today announced clinical trials to investigate the safety and efficacy of a synthetic antibody therapy in COVID-19 patients.…
Headline
The Centers for Medicare & Medicaid Services will allow health insurers to offer premium reductions for individuals with 2020 coverage in the individual…
Headline
The Department of Health and Human Services Friday released specifications for reporting certain COVID-19 laboratory data as required by the Coronavirus Aid,…
Headline
The U.S. District Court for the Southern District of New York yesterday ruled against the Department of Labor regarding its regulations related to certain…